Concert Pharmaceuticals
Biotechnology company
Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative...Founded in 2006
Homepage: http://www.concertpharma.com
Total money raised: $99.5M
Corporate Headquarters
02421 99 Hayden AvenueSuite 500
Lexington
USA MA
Phone: 781.860.0045
Concert Pharmaceuticals at CrunchBase
Steve Bernitz Chief Business Officer
Robert Silverman Vice President and General Counsel
Nancy Stuart COO
Robert Zelle Vice President, Drug Development
Past
February, 2012
June, 2011
Concert Pharmaceuticals raised $4M in unattributed round from GlaxoSmithKline
April, 2011
has made two new executive appointments
February, 2011
November, 2009
Concert Pharmaceuticals to land $12M from HIV drug's clinical study
April, 2008
Concert Pharmaceuticals raised $37M in a Series C round from QVT Financial, GSK Venture Fund, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, Skyline Ventures, TVM Capital, Brookside Capital, New Leaf Venture Partners, Flagship Ventures, Adage Capital Management, and Greylock Partners
November, 2006
Concert Pharmaceuticals raised $48.5M in a Series B round from Flagship Ventures, Brookside Capital, New Leaf Venture Partners, Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial
July, 2006
Concert Pharmaceuticals raised $10M in a Series A round from Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial
2006
Concert Pharmaceuticals was founded in 2006